 VICTORIA, British Columbia--BUSINESS WIRE--Aurinia Pharmaceuticals Inc. NASDAQ: AUPH TSX: AUP Aurinia or the Company, a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced today it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange TSX effective as of the close of trading on July 30, 2021. The Companys common shares will no longer be traded on the TSX but will continue to trade on the Nasdaq Ca 